Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Novo Nordisk AS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study. 2. Age 18 years or above at the time of signing the informed consent. 3. Presence of ASCVD and/or HF. 4. Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only).
Exclusion criteria
Exclusion criteria: 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Current participation (i.e., signed informed consent) in any other interventional clinical study. 3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. Clinical evidence, or suspicion of, active infection within the last 60 days. 5. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the prevalence of systemic inflammation (defined as hsCRP =2 mg/L) in pre-defined cohorts of patients with ASCVD and/or HF, and subgroups hereof.Timepoint: Primary objective will be assessed during subject visit date and there is only one subject visit in this study. | — |
Secondary
| Measure | Time frame |
|---|---|
| • To examine IL-6 stratified by the presence of systemic inflammation (defined as hsCRP =2 mg/L) in pre-defined cohorts of patients with ASCVD and/or HF, & subgroups hereof. • To examine NT-proBNP stratified by the presence of systemic inflammation (defined as hsCRP =2 mg/L) in pre-defined cohorts of patients with HF, & subgroups hereof. Timepoint: Secondary objective will be assessed during subject visit date & there is only one subject visit in this study. | — |
Countries
Argentina, Australia, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Republic of Korea, Sweden, United Kingdom, United States of America
Contacts
Public ContactJinu Jose
IQVIA RDS (India) Private Limited
Outcome results
None listed